Cell-penetrating fusion peptides OD1 and OD2 interact with Bcr–Abl and influence the growth and apoptosis of K562 cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cell-penetrating fusion peptides OD1 and OD2 interact with Bcr–Abl and influence the growth and apoptosis of K562 cells

Published:2013-10-05 Issue:1-2 Volume:385 Page:311-318
ISSN:0300-8177
Container-title:Molecular and Cellular Biochemistry
language:en
Short-container-title:Mol Cell Biochem

Author:

Wang Hai-xia,Xiao Heng,Zhong Liang,Tao Kun,Li Ya-juan,Huang Shi-feng,Wen Jian-ping,Feng Wen-li

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Clinical Biochemistry,Molecular Biology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s11010-013-1841-1.pdf

Reference21 articles.

1. Cross NC, White HE, Müller MC, Saglio G, Hochhaus A (2012) Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 26(10):2172–2175

2. Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM (1999) The biology of chronic myeloid leukemia. N Engl J Med 341:164–172

3. Landry WD, Woolley JF, Cotter TG (2013) Imatinib and nilotinib inhibit Bcr–Abl-induced ROS through targeted degradation of the NADPH oxidase subunit p22phox. Leuk Res 37(2):183–189

4. Kim TD, Türkmen S, Schwarz M, Koca G, Nogai H, Bommer C, Dörken B, Daniel P, le Coutre P (2010) Impact of additional chromosomal aberrations and Bcr–Abl kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia. Haematologica 95(4):582–588

5. Arlinghaus RB (2002) Bcr: a negative regulator of the Bcr–Abl oncoprotein in leukemia. Oncogene 21(56):8560–8567

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structure‐Guided Drug Design Targeting Abl Kinase: How Structure and Regulation Can Assist in Designing New Drugs;ChemBioChem;2024-09-12

2. Inhibition of Bcr-Abl in Human Leukemic Cells with a Coiled-Coil Protein Delivered by a Leukemia-Specific Cell-Penetrating Peptide;Molecular Pharmaceutics;2015-04-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3